Black Diamond Therapeutics initiates BDTX-1535 dosing for non-classical EGFR mutant NSCLC in Q1 2024.

Black Diamond Therapeutics, a clinical-stage oncology company, shared its Q1 2024 results. Focused on MasterKey therapies for cancer patients, it's leading drug candidate BDTX-1535 has initiated dosing for non-classical EGFR mutant NSCLC. Presentations at AACR and ASCO meetings are anticipated, with Phase 2 data expected in Q3 2024.

Articles

Eagle Tribune

Market Screener

Market Screener

-- show less --

Further Reading

Related Stories